Zika virus infectious disease

disease
On this page

Also known as congenital Zika syndromecongenital Zika virus infectionfever, ZikaZikaZika feverZika virus caused disease or disorderZika virus diseaseZika virus disease or disorderZika virus infectionZikV infection

Summary

Zika virus infectious disease (MONDO:0018661) is a disease and 47 clinical trials. Top therapeutic interventions include sodium chloride and japanese encephalitis virus, inactivated. A subtype of Flaviviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 34
  • Clinical trials: 47

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Annual incidence1-5 / 10 00058.8BrazilValidated

Signs & symptoms

Clinical features (HPO)

34 HPO clinical features (Orphanet curated; top 34 by frequency):

HPO IDTermFrequency
HP:0000988Skin rashVery frequent (80-99%)
HP:0040186Maculopapular exanthemaVery frequent (80-99%)
HP:0000509ConjunctivitisFrequent (30-79%)
HP:0000989PruritusFrequent (30-79%)
HP:0001369ArthritisFrequent (30-79%)
HP:0001945FeverFrequent (30-79%)
HP:0002315HeadacheFrequent (30-79%)
HP:0002829ArthralgiaFrequent (30-79%)
HP:0002921Abnormality of the cerebrospinal fluidFrequent (30-79%)
HP:0003326MyalgiaFrequent (30-79%)
HP:0003496Increased circulating IgM levelFrequent (30-79%)
HP:0000969EdemaOccasional (5-29%)
HP:0001225Wrist swellingOccasional (5-29%)
HP:0001785Ankle swellingOccasional (5-29%)
HP:0002013VomitingOccasional (5-29%)
HP:0012779Transient hearing impairmentOccasional (5-29%)
HP:0000252MicrocephalyVery rare (<1-4%)
HP:0000533Chorioretinal atrophyVery rare (<1-4%)
HP:0000612Iris colobomaVery rare (<1-4%)
HP:0001132Lens subluxationVery rare (<1-4%)
HP:0001287MeningitisVery rare (<1-4%)
HP:0001511Intrauterine growth retardationVery rare (<1-4%)
HP:0001873ThrombocytopeniaVery rare (<1-4%)
HP:0001933Subcutaneous hemorrhageVery rare (<1-4%)
HP:0002383Infectious encephalitisVery rare (<1-4%)
HP:0005268Spontaneous abortionVery rare (<1-4%)
HP:0006906Congenital intracerebral calcificationVery rare (<1-4%)
HP:0007131Acute demyelinating polyneuropathyVery rare (<1-4%)
HP:0007401Macular atrophyVery rare (<1-4%)
HP:0007766Optic disc hypoplasiaVery rare (<1-4%)
HP:0007814Retinal pigment epithelial mottlingVery rare (<1-4%)
HP:0012486MyelitisVery rare (<1-4%)
HP:0012795Abnormality of the optic discVery rare (<1-4%)
HP:0030825Absent foveal reflexVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical nameZika virus infectious disease
Mondo IDMONDO:0018661
MeSHD000071243
Orphanet448237
DOIDDOID:0060478
ICD-10-CMA92.5
ICD-111401438580
NCITC128423
SNOMED CT3928002
UMLSC0276289
MedGen547236
GARD0012894
Is cancer (heuristic)no

Also known as: congenital Zika syndrome · congenital Zika virus infection · fever, Zika · Zika · Zika fever · Zika virus caused disease or disorder · Zika virus disease · Zika virus disease or disorder · Zika virus infection · Zika virus infectious disease · ZikV infection

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseaseviral infectious disease › primary viral infectious disease › Flaviviridae infectious disease › Zika virus infectious disease

Related subtypes (9): Powassan encephalitis, Murray valley encephalitis, West Nile fever, dengue disease, pestivirus infectious disease, st. Louis encephalitis, Kyasanur forest disease, Omsk hemorrhagic fever, yellow fever

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 47.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified33
PHASE113
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03110770PHASE2COMPLETEDVRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
NCT02887482PHASE1COMPLETEDGLS-5700 in Dengue Virus Seropositive Adults
NCT02937233PHASE1COMPLETEDZika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study
NCT02952833PHASE1COMPLETEDZIKA Vaccine in Naive Subjects
NCT02963909PHASE1COMPLETEDA Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
NCT03008122PHASE1COMPLETEDPhase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area
NCT03343626PHASE1COMPLETEDSafety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
NCT03425149PHASE1COMPLETEDRandomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
NCT03624946PHASE1COMPLETEDStudy in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
NCT04015648PHASE1COMPLETEDSafety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)
NCT04033068PHASE1COMPLETEDSafety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
NCT04440774PHASE1COMPLETEDResearch Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.
NCT04478656PHASE1COMPLETEDSafety and Immunogenicity of BBV121
NCT06334393PHASE1COMPLETEDPhase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
NCT01386424Not specifiedRECRUITINGScreening for LID Clinical Studies Unit Healthy Volunteer Protocols
NCT04398901Not specifiedENROLLING_BY_INVITATIONNeurodevelopmental Outcomes in ZIKV-Exposed Children
NCT04615364Not specifiedRECRUITINGGenetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
NCT04619823Not specifiedRECRUITINGVirological and Immunological Determinants of Arbovirus Infection in New Caledonia
NCT07358910Not specifiedRECRUITINGRisk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
NCT07520279Not specifiedENROLLING_BY_INVITATIONXpert® Tropical Fever Test on GeneXpert® Edge X System
NCT02733796Not specifiedCOMPLETEDPersistence of Zika Virus in Semen After Acute Infection
NCT02831699Not specifiedCOMPLETEDThe Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
NCT02856984Not specifiedCOMPLETEDZika in Infants and Pregnancy (ZIP)
NCT03055585Not specifiedTERMINATEDApplying Wolbachia to Eliminate Dengue
NCT03158233Not specifiedCOMPLETEDZika Case Definition and Surveillance Study
NCT03161444Not specifiedTERMINATEDEstimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
NCT03204409Not specifiedWITHDRAWNZIKAlliance Natural History Study
NCT03206541Not specifiedCOMPLETEDNeurologic Manifestations of the Arbovirus Infection in Colombia
NCT03255369Not specifiedUNKNOWNVertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT03330600Not specifiedCOMPLETEDEfficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
NCT03631719Not specifiedCOMPLETEDImpact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
NCT03641339Not specifiedCOMPLETEDDefining Skin Immunity of a Bite of Key Insect Vectors in Humans
NCT03679728Not specifiedCOMPLETEDSensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection
NCT03776903Not specifiedCOMPLETEDEvaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
NCT04118738Not specifiedCOMPLETEDInternational Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy
NCT04343521Not specifiedCOMPLETEDQuantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
NCT04434846Not specifiedCOMPLETEDSylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
NCT04672577Not specifiedUNKNOWNInfection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
NCT04697147Not specifiedCOMPLETEDZika and Neurodevelopment Among Infants in Grenada
NCT05041439Not specifiedCOMPLETEDAdherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
SODIUM CHLORIDE42
JAPANESE ENCEPHALITIS VIRUS, INACTIVATED41
CHEMBL28380701